Avastin Approved in Europe for First-line Treatment of Patients With Advanced Lung Cancer
First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients
28-Aug-2007 -
Avastin (bevacizumab), Roche's anti-cancer drug, was approved in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.
The approval is based on data from the pivotal US phase III trial (E4599) and the ...
histology
kidney cancer
lung cancer
+3